Table 4.
Progression-free survival, median OS, and survival at 12 and 24 months (95% CI) at the time of long-term follow-up analysis (237 events observed)
n | Median PFS | Median OS | 12 mo OS | 24 mo OS | |
---|---|---|---|---|---|
Depatux-M + TMZ | 88 | 2.7 (2.0, 3.8) | 9.6 (7.4, 11.8) | 39.7 (29.4, 49.7) | 19.8 (12.2, 28.8) |
Depatux-M | 86 | 1.9 (1.9, 2.2) | 7.9 (6.1, 8.7) | 26.7 (17.9, 36.4) | 10.0 (4.8, 17.6) |
Lomustine or TMZ | 86 | 1.9 (1.8, 2.0) | 8.2 (5.9, 9.5) | 28.2 (19.1, 37.9) | 5.2 (1.7, 11.7) |